Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

Today's Research Daily features a real-time update on the Q4 earnings season and fresh Chevron (CVX), Merck (MRK), QUALCOMM ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...